REG - ReNeuron Group plc - Directorate Changes

ReNeuronAnnouncement

22/03/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220322:nRSV5218Fa&default-theme=true

RNS Number : 5218F  ReNeuron Group plc  22 March 2022

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Directorate Changes

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes
Technologies, announces that Dr Tim Corn and Mark Evans have resigned as
Non-Executive Directors of the Company and that Martin Walton has been
appointed as a Non-Executive Director, all with immediate effect.

 

Following these changes, the ReNeuron Board now comprises of five directors as
follows: Iain Ross (Executive Chairman); Catherine Isted (CFO and Executive
Director) and three independent Non-Executive Directors - Dr Michael Owen,
Barbara Staehelin and Martin Walton.

 

Iain Ross, Chairman of ReNeuron, commented: "On behalf of the Board and
Management I would like to thank Tim Corn for his service to the Company over
the last nine years and to recognise his contribution as a director and former
Chairman of ReNeuron. Also, I want to thank Mark Evans for the invaluable
support he has provided over the last two years as a director and
representative of Obotritia, a significant shareholder in ReNeuron.

 

"I would like to welcome Martin Walton to the ReNeuron Board as we look to
re-focus the business. Martin, a former investment banker, has completed more
than 25 transactions in the last 12 years as a principal or advisor which has
included start-up and spin-out investments, pre-IPO and IPO funding; M&A
and over $1bn in investment and co-investment capital. He is the co-founder of
LSE-listed Arix Bioscience plc (LSE: ARIX) and his current roles include
serving as CEO of Excalibur Medicines Ltd and a Board Member of the Liverpool
Life Sciences Accelerator Partnership.  He brings a wealth of relevant
experience in the life sciences sector."

 

As required under Schedule Two, paragraph (g) of the AIM Rules for Companies,
further disclosures on Mr Walton are as follows:

Martin Charles Walton, aged 58, has held the following directorships and/or
partnerships in the past five years:

 

 Current directorships and/or partnerships:  Past directorships and/or partnerships:
 Excalibur Medicines Ltd                     Igraine plc

 Bradshaw Consulting Ltd                     Iatros Capital Limited

 Interrad Medical Inc                        Iota Sciences Limited

                                             Simbec-Orion Group Limited

                                             PZT Limited

                                             Anontec Limited

                                             Arix Capital Management Limited

                                             Arthurian Life Sciences Gp Limited

                                             Arthurian Life Sciences Spv Gp Limited

                                             Excalibur Fund Managers Limited

 

There is no further information in respect of Mr Walton that is required to be
disclosed under AIM Rule 17 or Schedule Two, paragraph (g) of the AIM Rules
for Companies.

 

ENDS

 

 

Contacts:

 

 ReNeuron                                          www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                               Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Liberum Capital Limited (NOMAD and Joint Broker)  +44 (0)20 3100 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)            +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)          +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus                                      +44 (0)7980 541 893

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAMZGZFGMVGZZZ